Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral …

RC Kalayjian, RN Machekano, N Rizk… - The Journal of …, 2010 - academic.oup.com
RC Kalayjian, RN Machekano, N Rizk, GK Robbins, RT Gandhi, BA Rodriguez, RB Pollard…
The Journal of infectious diseases, 2010academic.oup.com
Abstract (See the article by Neuhaus et al, on pages 1788–1795, and the editorial
commentary by Dubé and Sattler, on pages 1783–1785.) Background. To identify
inflammatory pathways that may contribute to the pathogenesis of human immunodeficiency
virus (HIV) disease, we explored associations between AIDS or death and different
inflammatory markers, including selected soluble tumor necrosis factor superfamily
receptors (sTNFRs) and ligands, interleukin (IL)-6, and CD8 T cell activation, in individuals …
Abstract
(See the article by Neuhaus et al, on pages 1788–1795, and the editorial commentary by Dubé and Sattler, on pages 1783–1785.)
Background. To identify inflammatory pathways that may contribute to the pathogenesis of human immunodeficiency virus (HIV) disease, we explored associations between AIDS or death and different inflammatory markers, including selected soluble tumor necrosis factor superfamily receptors (sTNFRs) and ligands, interleukin (IL)-6, and CD8 T cell activation, in individuals treated with highly active antiretroviral therapy (HAART).
Methods. A case-control study of subjects in AIDS Clinical Trials Group (ACTG) protocols 384 and 5015, who were matched according to the CD4 cell count and plasma viral load at baseline, was performed using conditional logistic regression.
Results. Higher pretreatment concentrations of sTNFR-1, sCD27, sCD40L, and plasma IL-6 were associated with a new AIDS-defining illness or death in separate models adjusted for age, sex, hemoglobin, and the latest CD4 cell counts. In additional models that excluded case patients with opportunistic infections, sTNFR-1, sCD27, and sCD40L were each associated with a new AIDS-defining malignancy or death that developed at a median of 51 weeks after initiation of HAART, by which time the majority of subjects had a CD4 cell count of >200 cells/cm3 and had achieved a plasma viral load of <50 copies/mL.
Conclusion. These data are compatible with a model in which these soluble inflammatory markers identify pathways that may contribute to the pathogenesis of HIV disease progression, pathways that might not be a direct consequence of ongoing HIV type 1 replication.
Oxford University Press